10-Q: Anebulo Pharmaceuticals Reports Q3 2025 Results, Prioritizes IV Selonabant for Pediatric Cannabis Toxicity

Anebulo Pharmaceuticals focuses on developing intravenous selonabant for pediatric cannabis-induced toxicity while reporting financial results for the quarter ended March 31, 2025.

Summary

• Anebulo Pharmaceuticals, a clinical-stage pharmaceutical company, is focusing on developing treatments for cannabis-induced toxicity.
• The company's lead product candidate, selonabant, is intended to reverse the negative effects of cannabis-induced toxicity.
• Anebulo is prioritizing the advancement of an intravenous (IV) formulation of selonabant for pediatric patients with cannabis-induced CNS depression.
• The company met with the FDA in December 2024 to discuss the development of IV selonabant and the initial plan for clinical testing.
• A single ascending dose (SAD) study of IV selonabant in healthy adults is planned for the third quarter of calendar 2025, pending FDA clearance.
• The company had cash and cash equivalents of approximately $13.3 million as of March 31, 2025.
• Anebulo expects its cash and cash equivalents, along with available funding under a Loan Agreement, will be sufficient to fund operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial statements.
• The company reported a net loss of approximately $6.3 million for the nine-month period ended March 31, 2025.
• Research and development expenses for the three and nine months ended March 31, 2025 were $638,324 and $3,173,718, respectively.
• General and administrative expenses for the three and nine months ended March 31, 2025 were $1,253,998 and $3,718,879, respectively.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is making progress on its clinical development program and has sufficient cash to fund its operations for the near term. However, it is still incurring losses and will need to raise additional capital in the future.

Positives

• Anebulo is focusing on a critical unmet need: developing a treatment for cannabis-induced toxicity in children.
• The company has a clear development plan for IV selonabant, with a planned SAD study in adults in Q3 2025.
• Anebulo has a solid cash position of $13.3 million as of March 31, 2025.
• The company has access to additional funding through a Loan Agreement.
• Anebulo is receiving grant funding from NIDA to support the development of IV selonabant.

Negatives

• Anebulo has incurred significant operating losses since inception and expects to continue to do so.
• The company has not generated any revenue since inception.
• Anebulo will need to raise additional capital in the future.
• The company is dependent on the results of clinical studies relating to its product and the products of its competitors.

Risks

• The company's future success depends on the outcome of clinical trials and regulatory approvals.
• Anebulo faces competition from other companies developing treatments for cannabis-induced toxicity.
• The company's ability to commercialize its product candidates depends on market acceptance and reimbursement by third-party payors.
• Anebulo may face third-party claims of intellectual property infringement.
• The company is dependent on key individuals and sole-source suppliers.

Future Outlook

Anebulo expects its cash and cash equivalents, along with available funding under the Loan Agreement, will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial statements; the company plans to initiate a single ascending dose (SAD) study of IV selonabant in healthy adults in the third quarter of calendar 2025, subject to clearance of the protocol by FDA.

Management Comments

• FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication.

Industry Context

The increasing legalization of cannabis is leading to a rise in cannabis-related emergency room visits, creating a need for treatments like selonabant.

Comparison to Industry Standards

• It is difficult to compare Anebulo directly to industry standards due to its unique focus on cannabis-induced toxicity.
• However, other pharmaceutical companies developing treatments for substance abuse and related conditions include Alkermes, Indivior, and Opiant Pharmaceuticals.
• These companies often focus on opioid addiction, but there is increasing interest in developing treatments for cannabis-related disorders.
• Anebulo's approach of targeting the CB1 receptor with selonabant is similar to strategies used in other areas of addiction treatment.
• The company's decision to prioritize an IV formulation for pediatric patients reflects a growing awareness of the specific risks associated with cannabis exposure in children.

Stakeholder Impact

• Shareholders: The company's focus on IV selonabant for pediatric patients could lead to a faster path to approval and increased shareholder value.
• Patients: The development of selonabant could provide a much-needed treatment for cannabis-induced toxicity.
• Employees: The company's continued progress could lead to job growth and opportunities for advancement.

Next Steps

• Initiate a single ascending dose (SAD) study of IV selonabant in healthy adults in the third quarter of calendar 2025, subject to FDA clearance.
• Continue to develop IV selonabant for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression in children.
• Continue to seek additional equity or debt financing or potential collaboration, license or development agreements to provide the capital required to maintain or expand operations.

Key Dates

Keywords

selonabant, cannabis-induced toxicity, acute cannabinoid intoxication, pediatric, intravenous, clinical trials, FDA, NIDA, pharmaceutical, ANEB